CCNE1 and ovarian carcinoma: We selected the 100 mg/kg twice daily dose and tested three additional in vivo models of CCNE1-amplified cancer: a second PDX model of gastric adenocarcinoma (GA0114, CCNE1 copy number <3), an ovarian carcinoma PDX model OV5398 (CCNE1 copy number <9), and a cell-derived xenograft (CDX) model OVCAR-3 (CCNE1 copy number <10; ref. 22).